Effects of Metabolic syndrome
Metabolic syndrome (MetS) is allied with abdominal obesity, blood lipid disorders, inflammation, insulin resistance, diabetes, and increased risk of developing cardiovascular disease (CVD) and also finally death [1,2,3]. The prevalence of this sorting affects nearly 1 in 3 adults in the United States. Due to the high frequency of this syndrome, proper documentation of persons with MetS is vital in order to prevent and/or alter the multiple predictor variables associated with CVD related disease and mortality as well as its high healthcare costs [5-9]. The lethal consequences are probably due to the smoking and excess weight induced chronic inflammatory development on the endothelial system for a long run. White coat hypertension (WCH) is a first sign of the accelerated systemic atherosclerotic process which can be easily detected and treated by preventing weight gain. Diabetes is the largest non-contagious disease, currently affected are more than 382 million people aged between 20-79 years across the globe and type 2 diabetes indisputably is the main underlying subtype [10,11]. Type two diabetes mellitus (T2DM) is the main leading factor to cardiovascular mortality worldwide. . Nevertheless, both clinical conditions T2DM and MetS are considered as high risk factors that are responsible for cardiovascular outcomes through collaboration of similar pathogenesis’ mechanisms . Common to these diseases of metabolism is the associated development of Atherosclerotic Cardiovascular Disease (ASCVD). Studies have shown a strong link between CMS and increased prevalence of peripheral vascular diseases, corona artery disease and myocardial infarctions as well as cerebro-vascular arterial diseases and stroke . It consists of atherogenic dyslipidemia elevations of blood pressure (BP) and glucose, and prothrombotic and proinflammatory states [14-16].Metalic syndrome is considered as Obesity faced by many people. The constellation of Excess of lipids especially cholesterol, elevated blood pressure, impaired glucose tolerance, and central obesity is now classified as metabolic syndrome, also called syndrome X [16-18].
Jhansi Rani G, Srilatha D